A significant body of work from the Smyth group performed in various mouse cancer models suggests that CD96 might limit NK cell-mediated protection against metastases and, therefore, blocking CD96 would enhance NK cell production of IFN-γ and cancer control [44,69,70]. The gene discussed is IFNG; the disease is cancer.